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The clinical significance of L-type amino acid transporter 1 (LAT1) expression remains unclear, whereas many experimental studies
have demonstrated that LAT1 is associated with the proliferation of cancer cells. The purpose of this study was to evaluate the
prognostic value of LAT1 in patients with nonsmall cell lung cancer (NSCLC). A total of 321 consecutive patients with completely
resected pathologic stage I–III NSCLC were retrospectively reviewed. Expression of LAT1 and proliferative activity, as determined by
the Ki-67 labelling index, was also evaluated immunohistochemically and correlated with the prognosis of patients who underwent
complete resection of the tumour. Expression of LAT1 was positive in 163 patients (51%) (29% of adenocaricnoma (58 of 200
patients), 91% of squamous cell carcinoma (91 of 100 patients), and 67% of large cell carcinoma (14 of 21 patients)). The 5-year
survival rate of LAT1-positive patients (51.8%) was significantly worse than that of LAT1-negative patients (87.8%; Po0.001). L-type
amino acid transporter 1 expression was significantly associated with lymph node metastasis and disease stage. Multivariate analysis
confirmed that positive expression of LAT1 was an independent factor for predicting a poor prognosis. There was a significant
correlation between LAT1 expression and Ki-67 labelling index. LAT1 expression is a promising pathological factor to predict the
prognosis in patients with resectable stage I–III NSCLC.
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Nonsmall cell lung cancer (NSCLC) is the leading cause of cancer
death and has a poor prognosis (Shottenfeld, 1996). To improve
the prognosis of patients, clinical markers that may predict the
prognosis and response to the specific therapy should be
established. Tumour staging and performance status have been
consistently shown to be the most powerful prognostic tool for
survival rates of NSCLC patients (Brundage et al, 2002). The
prognostic factors such as ‘N’ factor, tumour size, sex, and vessel
invasion have been shown to determine overall outcome in
patients with surgically resected NSCLC (Brundage et al, 2002).
Recently, excision repair cross-complementation group 1 has been
described to be a new promising marker for drug response and
overall survival in NSCLC patients (Olaussen et al, 2006). However,
there has been no established clinical marker, which correlates
with the response to the treatment and the prognosis in patients
with NSCLC (Clinical practice guidelines for the treatment of
unresectable nonsmall cell lung cancer, 1997).
Amino acid transporters are essential for growth and prolifera-
tion in normal and transformed cells (Christensen, 1990; McGivan
and Pastor-Anglada, 1994). Among amino acid transporters,
system L is a Na
þ-independent large and neutral amino acid
transport agency (Oxender and Christensen, 1962; Christensen,
1990). L-type amino acid transporter 1 (LAT1) is one of the L-type
amino acid transporters, and transports large neutral amino acids
such as leucine, isoleucine, valine, phenylalanine, tyrosine,
tryptophan, methionine and histidine (Oxender and Christensen,
1962; Kanai et al, 1998; Yanagida et al, 2001). L-type amino acid
transporter 1 requires covalent association with the heavy chain of
4F2 cell surface antigen (4F2hc) for its functional expression in
plasma membrane (Oxender and Christensen, 1962). Previous
studies have shown LAT1 to be highly expressed in proliferating
tissues, many tumour cell lines (T24 bladder carcinoma cells,
RERF-LC-MA lung small-cell carcinoma cells, and HeLa uterine
cervical carcinoma cells) and primary human tumours (Yanagida
et al, 2001). It has been reported that LAT1 expression is closely
related to tumour cell growth of liver metastases in a rat model
(Ohkame et al, 2001). Recent studies demonstrated the over-
expression of LAT1 in pulmonary adenocarcinoma and oesopha-
geal carcinoma (Kobayashi et al, 2005; Nakanishi et al, 2006). High
LAT1 immunostaining was described to predict a poor prognosis
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sin patients with astrocytic brain tumours (Nawashiro et al, 2006).
The RNA interference to downregulate LAT1 has been described
to impair the proliferation of human oral cancer cells (Kim et al,
2006). Although many experimental studies have clearly
indicated that LAT1 is associated with cancerous or proliferative
cells, the clinical significance of LAT1 expression in NSCLC
remains unclear (Yanagida et al, 2001; Nakanishi et al, 2006).
Since there is no clinical study on LAT1 expression in NSCLC,
the correlation between LAT1 expression and prognosis is
also unknown. In this study, therefore, the pathological
findings including LAT1 expression was assessed in the resected
tissue specimen and correlated with clinical feature and
outcome. In addition, LAT1 expression was correlated with the
proliferative activity of the tumour as assessed by the Ki-67
labelling index.
MATERIALS AND METHODS
Patients
We analysed 361 consecutive patients with NSCLC who underwent
resection either by lobectomy or pneumonectomy with mediastinal
lymph node dissection at Gunma University Hospital between June
1998 and May 2004. Nineteen patients who received induction of
chemotherapy or radiation therapy and one patient who suffered
from an operation-related death were excluded. Specimens of 20
patients were not available. A total of 321 patients (196 men, 125
women) were evaluated. The study protocol was approved by the
institutional review board.
The age of the patients ranged from 39 to 84 years, and the mean
age at the time of surgery was 67 years. The tumour specimens
were histologically classified according to the criteria of the World
Health Organization. Postsurgical pathologic stage was determined
by the current tumour-node-metastasis classification (Mountain,
1997). Histologically, 200 patients had adenocarcinoma, 100 had
squamous cell carcinoma (SQC), and 21 had large cell carcinoma
(LCC). Of the total patients, 241, 28 and 52 had stage I, II and III
tumours, respectively. As postoperative adjuvant therapies,
platinum-based chemotherapy, radiation, and oral administration
of tegafur (a fluorouracil derivative drug) were administered to 27,
14, and 35 patients, respectively. Intraoperative therapy was not
performed on any patient. The postoperative clinical course was
assessed by analysing outpatient medical records and by marking
telephone inquiries. The day of surgery was considered the starting
day for counting postoperative survival. The follow-up duration
ranged from 6 to 86 months (median, 48 months).
Immunohistochemical staining with LAT1 and Ki-67
LAT1 L-type amino acid transporter 1 expression was deter-
mined by immunohistochemical staining with an affinity-purified
polyclonal rabbit anti-human LAT1 antibody (Yanagida et al,
2001). An oligopeptide corresponding to amino acid residues 497–
507 of human LAT1 (CQKLMQVVPQET) was synthesized. The N-
terminal cysteine residue was introduced for conjugation with
keyhole limpet hemocyanine. Antipeptide antibody was produced
as described elsewhere (Chairoungdua et al, 1999). For immuno-
histochemical analysis, antiserum was affinity-purified as de-
scribed previously (Chairoungdua et al, 1999).
Immunohistochemical staining was performed on paraffin
sections using a polymer peroxidase method (Envisionþ/HRP;
Dako Cytomation CO., Ltd., Denmark). Briefly, deparaffinised and
rehydrated sections were treated with 0.3% hydrogen peroxide in
methanol for 30min to block endogenous peroxidase activity. To
expose antigens, sections were autoclaved in 10mmoll
 1 sodium
citrate buffer (pH 6.0) for 5min, and cooled for 30min. After
rinsing in 0.05M tris-buffered saline containing 0.1% tween 20, the
sections were incubated with affinity-purified anti-LAT1 antibody
(1.2mgml
 1; 1:3200) overnight at 41C. Thereafter, they were
incubated with Envision (þ) rabbit peroxidase (Dako, Carpinteria,
CA, USA) for 30min. The peroxidase reaction was performed
using 0.02% 3,30-diaminobenzidine tetrahydrochloride and 0.01%
hydrogen peroxide in 0.05M tris–HCl buffer, pH 7.4. Finally,
nuclear counterstaining was performed with Mayer’s hematoxylin.
For negative control, incubation step with the primary antibody
was omitted. The specificity of immunoreactions using the anti-
LAT1 antibody was established in previous studies (Matsuo et al,
2000; Nawashiro et al, 2006).
LAT1 expression was considered positive only if distinct
membrane staining was present. Staining intensity was scored as
follows: (1) o10% of tumour area stained; (2) 11–25% stained; (3)
26–50% stained; and (4) X51% stained. The tumours in which
stained tumour cells made up more than 10% of the tumour were
graded as positive. According to this scoring protocol, two
investigators from the authors, without prior knowledge of the
clinical data, independently graded the staining intensity in all
cases. To test the intraobserver variability, each section was
reassessed by the same investigators after the first assessment had
been completed. The time interval between the first and second
assessments was at least 4 weeks. The interobserver variability was
also determined by comparing the values of the first measurements
of two investigators.
Ki-67 The detailed protocol for immunostaining was published
elsewhere (Buck et al, 2001). Briefly, formalin-fixed and paraffin-
embedded sections of resected specimens were dewaxed,
rehydrated, trypsinized, and boiled in 0.01mol/l. citrate buffer
for 30min. For immunostaining, the monoclonal mouse antibody
MIB-1 (Dako, Denmark), specific for human nuclear antigen Ki-67,
was used in a 1:40 dilution. The sections were lightly counter-
stained with hematoxylin. As a positive control for proliferating
cells, sections of tonsil were used.
A highly cellular area of the immunostained sections was
evaluated. All epithelial cells with nuclear staining of any intensity
were defined as positive. Approximately 1000 nuclei were counted
on each slide. Proliferative activity was assessed as the percentage
of MIB-1-stained nuclei in the sample. Ki-67 expression was
defined as low if less than 25% of tumour cells showed staining in
nuclei in a tumour section. This definition was used according
to the commonly used cutoff values ranging from 20 to 40% in
NSCLC and other human cancers in the current literature (Martin
et al, 2004) and also based on the examination of our staining data.
Sections were evaluated by two investigators separately and in case
of discrepancies both would evaluate the slide simultaneously and
would agree in their final assessment. Neither investigators had
knowledge of patient outcome.
Statistical analysis
The w
2-test and Fisher’s exact test was used to examine the
association of two categorical variables. Correlations between
LAT1 expression and Ki-67 labelling index were analysed by using
the nonparametric Spearman’s rank test.
Survival time was determined as the time from tumour resection
to death from any cause. For survivors, survival times were
censored on the last date that patients were known to be alive. The
Kaplan–Meier method was used to estimate survival as a function
of time, and survival differences were analysed by the log-rank test.
Multivariate analyses were performed using stepwise Cox propor-
tional hazards model to identify independent prognostic factors. A
P-value less than 0.05 was considered indicative of statistical
significance. Statistical analysis was performed using StatView
J-4.5 for Macintosh.
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Expression of LAT1 in NSCLC
L-type amino acid transporter 1 immunostaining was detected in
carcinoma cells in tumour tissues and localised predominantly
on their plasma membrane (Figure 1). In the present study, no
expression of LAT1 protein was observed in any normal epithelial
cells of the lung, including bronchial epithelial and alveolar cells.
All positive cells revealed strong membranous LAT1 immuno-
staining. It is worthy to note that the staining intensity of the cell
membrane and the percentage of positive cells were considerably
greater in SQC and LCC than AC. The cytoplasmic staining was
rarely evident. Expression of LAT1 was positive in 51% (163 of 321
patients) (29% of AC (58 of 200 patients), 91% of SQC (91 of 100
patients), and 67% of LCC (14 of 21 patients)). The incidence of a
positive LAT1 expression was significantly different between AC
and SQC (Po0.001) and between AC and non-AC (Po0.001). The
average score of the LAT1 expression was 2.0±1.2 on a scale of
1–4. The LAT1 score was 1.5±0.8 in AC, 3.1±1.0 in SQC and
2.5±1.3 in LCC. There was a significant difference in the LAT1
score between AC and SQC (Po0.001) and between AC and LCC
(Po0.001).
Expression of LAT1 according to patient’s characteristics is
listed in Table 1. In NSCLC, LAT1 expression was significantly
associated with gender, tumour size, lymph node metastasis,
disease stage, lymphatic permeation, vascular permeation, and
pleural involvement. In AC, LAT1 expression was significantly
associated with gender, lymph node metastasis, disease stage,
lymphatic permeation, vascular permeation, and pleural involve-
ment. In SQC, LAT1 expression was significantly associated with
lymph node metastasis.
LAT1 expression and postoperative survival
Postoperative survival according to LAT1 status is listed in Table 2.
For all patients, the 5-year survival rates of the LAT1-positive and
LAT1-negative patients were 51.8 and 87.8%, respectively,
demonstrating a significantly poor prognosis for LAT1-positive
patients (Po0.001, Figure 2A, B and C). Postoperative survival was
also analysed by age, gender, and pathologic stage. For pathologic
stage I disease, the 5-year survival rates of LAT1-positive and
LAT1-negative patients were 67.9 and 90.9%, respectively,
demonstrating a significantly poor prognosis for the LAT1-positive
patients (Po0.001, Table 2). For pathologic stage II and III disease,
the 5-year survival rates of LAT1-positive and LAT1-negative
patients were 25.6 and 68.3%, respectively, demonstrating a
significantly poor prognosis for the LAT1-positive patients
(P¼0.021, Table 2). A significant difference in the prognosis
between the LAT1-positive and LAT1-negative patients was also
demonstrated for age and gender (Table 2).
LAT1 and Ki-67 expression
The Ki-67 labelling index averaged 35±24% (median, 32%) and
ranged from 5 to 92% in NSCLC. The Ki-67 labelling index was
23±20% (median, 18%) in AC, 54±17% (median, 56%) in SQC
Figure 1 Immunohistochemical analysis of LAT1 in NSCLC. (A) Positive staining of LAT1 expression in squamous cell carcinoma. The score of LAT1
immunostaining was grade 4 and its immunostaining pattern was membranous. (B) LAT1 expression in squamous cell carcinoma with staining score of grade
2. (C) LAT1 expression in adenocarcinoma with staining score of grade 3. (D) LAT1 expression in large cell carcinoma with staining score of grade 4.
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significantly different between AC and SQC (Po0.001) and
between AC and LCC (Po0.001).
Significant correlation was found between LAT1 expression and
Ki-67 labelling index (Spearman’s rank correlation coefficient
g¼0.772, Po0.001) in NSCLC (AC (g¼0.5817, Po0.001), SQC
(g¼0.6917, Po0.001), and (LCC (g¼0.7947, Po0.001)) (Figure 3).
Moreover, Kaplan–Meier analysis demonstrated that 5-year
survival rate of patients with high Ki-67 labelling index tumours
significantly decreased in comparison with those with low Ki-67
labelling index tumours (57.5 vs 89.2%; Po0.001) (Figure 2D).
Multivariate analysis of prognostic factors
Multivariate analysis confirmed that positive expression of LAT1
was an independent and significant factor to predict a poor
prognosis. Pathologic stage was also a significant prognostic factor
(Table 3).
DISCUSSION
The present study evaluated the clinical significance of LAT1
expression in NSCLC. The results of the study clearly demon-
strated that the expression of LAT1, and the pathologic disease
stage, was a significant independent factor to predict a poor
prognosis in patients with completely resected NSCLC. Moreover,
our study has shown that LAT1 expression was significantly
associated with lymph node metastasis and disease stage.
It is widely known that amino acid transport systems play an
important role in the regulation of cellular proliferation, whereas
the details of its function to promote tumour cell proliferation
have not been clarified (Kanai et al, 1998). Full-length LAT1 was
Table 1 Association between LAT1 expression and the clinicopathological features
All
a Adenocarcinoma Squamous cell carcinoma
LAT1 positive LAT1 positive LAT1 positive
Parameter No. No. (%) P-value No. No. (%) P-value No. No. (%) P-value
Total 321 163 (51) 200 58 (29) 100 91 (91)
Age
p65 years 105 45 (43) 0.186 77 20 (26) 0.280 20 18 (90) 0.74
465 years 216 118 (55) 123 38 (31) 80 73 (91)
Gender
Male 205 131 (64) o0.001
b 94 34 (36) 0.025 92 83 (90) 0.456
Female 116 32 (28) 106 24 (23) 8 8 (100)
Tumour size (mm)
p30 159 84 (53) 0.022 108 38 (35) 0.738 47 42 (89) 0.423
430 124 81 (65) 54 21 (39) 53 49 (92)
Lymph node metastasis
Positive 56 39 (70) o0.001 30 16 (52) o0.001 18 18 (100) o0.001
Negative 265 24 (9) 170 14 (8) 82 0 (0)
Disease stage (p-stage)
I 241 104 (43) o0.001 164 38 (23) o0.001 69 61 (88) 0.59
II+III 80 61 (76) 36 21 (58) 15 14 (93)
Lymphatic permeation
Positive 126 87 (69) o0.001 65 31 (48) o0.001 51 46 (90) 0.526
Negative 194 77 (40) 135 27 (20) 49 45 (92)
Vascular invasion
Positive 94 64 (68) o0.001 45 19 (42) 0.022 40 36 (90) 0.74
Negative 227 100 (44) 155 39 (25) 60 55 (92)
Pleural involvement
Positive 103 66 (64) o0.001 55 25 (45) o0.001 34 30 (88) 0.855
Negative 219 98 (45) 145 33 (23) 66 61 (92)
LAT1¼L-type amino acid transporter 1.
aLarge cell carcinoma was included.
bStatistically significant.
Table 2 Five-year survival according to LAT1 expression
Five-year survival rate (%)
a
Variable LAT1 positive LAT1 negative P-value
b
All patients 51.8 87.8 o0.001
Age
p 65 years 60.0 90.0 0.008
465 years 46.9 83.1 o0.001
Gender
Male 47.7 79.3 0.006
Female 63.9 98.2 o0.001
Pathologic stage
I 67.9 90.9 o0.001
II+III 25.6 68.3 0.021
LAT1¼L-type amino acid transporter 1.
aKaplan–Meier analysis.
bLog-rank test.
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sfirst isolated and characterised in 1998 (Kanai et al, 1998). LAT1 is
widely expressed in primary human cancers and several cancer cell
lines, where it has been shown to play essential roles in growth and
survival (Fuchs and Bode, 2006). While it is currently unclear why
LAT1 is coveted by transformed cell, Fuchs et al hypothesize that
LAT1 provides the essential amino acids that act as signal to
enhance growth of cancer cells via mammalian target-of-rapamycin
(mTOR)-stimulated translation (Fuchs and Bode, 2006). Likewise,
mTOR regulates amino acid transporter gene expression and
trafficking to the plasma membrane in response to the growth
signal (Fuchs and Bode, 2006). Moreover, overexpression of LAT1
was described to be associated with metastasis in vivo (Ohkame
et al, 2001; Tamai et al, 2001). When colon cancer RCN-9 cells were
injected into the spleen of rats, the size of the resultant metastatic
liver tumours was directly correlated to LAT1 expression (Ohkame
et al, 2001; Tamai et al, 2001). Thus, inhibition of LAT1 function
could be a potential therapeutic strategy for many types of cancer
(Kanai and Endou, 2001; Fuchs and Bode, 2006). Whereas, LAT1
has been shown to mediate the uptake of a number of amino acid-
related compounds such as L-dopa, triiodothyronine, thyroxin,
and the anti-cancer agent melphalan (L-phenylalanine mustard,
L-PAM, Alkeran, L-Sarcolysin) (Uchino et al, 2002). LAT1 appears
to have opposing roles for the growth of cancer cell and also the
suppression of the growth. It is a potential target per se because it
supplies tumour cells with essential amino acids necessary for
protein synthesis and cell growth. Conversely, its upregulation in a
variety of cancers might be exploited for anti-tumour drugs like
melphalan.
L-type amino acid transporter 1 protein overexpression in
bronchioalveolar carcinoma is shown to associate with the Ki-67
labelling index, indicating an upregulation of metabolic activity
(Nakanishi et al, 2006). Our result revealed that Ki-67 labelling
index is significantly correlated with LAT1 expression in NSCLC.
Ki-67 labelling index in SQC and LCC was significantly higher than
that in AC. A meta-analysis indicated that the expression of Ki-67
is a factor of poor prognosis for survival in NSCLC (Martin et al,
2004). The present study revealed that high Ki-67 labelling index is
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Figure 3 Correlation of LAT1 expression with Ki-67 labelling index
(g¼0.772, Po0.001).
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sassociated with an unfavourable prognosis in patients with
completely resected NSCLC.
We examined LAT1 expression immunohistochemically and
found that LAT1 expression in SQC and LCC was significantly
higher than that in AC. Since the LAT1 expression was
significantly correlated with Ki-67 labelling index, the incidence
of LAT1 expression in NSCLC may be associated with tumour cell
proliferation. However, the reason why the incidence of LAT1
expression was different among the histopathologic subtypes is not
known and remained to be elucidated.
Several clinical investigations demonstrated the increased
uptake of radiolabelled amino acids in human neoplasms (Inoue
et al, 2001; Oriuchi et al, 2006; Kaira et al, 2007b). We have
developed L-[3-
18F]-a–methyltyrosine (FMT) as a tracer for amino
acid transport using positron emission tomography (PET) imaging
(Tomiyoshi et al, 1997), and investigated the clinical utility of FMT
in several tumours including brain tumour, lung cancer, head and
neck cancer, and lymphoma (Oriuchi et al, 2006). FMT is
transported via L-type amino acid transporter, which is specific
to cancer cells (Kim et al, 2002; Oriuchi et al, 2006; Kaira et al,
2007b). Recently, we reported a significant correlation between
FMT uptake and LAT1 expression in NSCLC (Kaira et al, 2007a).
In conclusion, positive expression of LAT1 is a significant factor
to predict poor prognosis, and it may be an important clinical
marker of therapy for NSCLC. LAT1 expression was significantly
correlated with tumour cell proliferation. Inhibiting LAT1 function
may cause a cessation of the growth of tumour and provide new
and effective therapeutic target of NSCLC in the future.
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